Ran Song
Seoul National University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ran Song.
Arthritis & Rheumatism | 2009
Xiaodong Zhou; Jong Eun Lee; Frank C. Arnett; Momiao Xiong; Min Young Park; Yeon Kyeong Yoo; Eun Soon Shin; John D. Reveille; Maureen D. Mayes; Jin Hyun Kim; Ran Song; Ji Yong Choi; Ji Ah Park; Yun Jong Lee; Eun Young Lee; Yeong Wook Song; Eun Bong Lee
OBJECTIVE To identify systemic sclerosis (SSc) susceptibility loci via a genome-wide association study. METHODS A genome-wide association study was performed in 137 patients with SSc and 564 controls from Korea using the Affymetrix Human SNP Array 5.0. After fine-mapping studies, the results were replicated in 1,107 SSc patients and 2,747 controls from a US Caucasian population. RESULTS The single-nucleotide polymorphisms (SNPs) (rs3128930, rs7763822, rs7764491, rs3117230, and rs3128965) of HLA-DPB1 and DPB2 on chromosome 6 formed a distinctive peak with log P values for association with SSc susceptibility (P=8.16x10(-13)). Subtyping analysis of HLA-DPB1 showed that DPB1*1301 (P=7.61x10(-8)) and DPB1*0901 (P=2.55x10(-5)) were the subtypes most susceptible to SSc in Korean subjects. In US Caucasians, 2 pairs of SNPs, rs7763822/rs7764491 and rs3117230/rs3128965, showed strong association with SSc patients who had either circulating anti-DNA topoisomerase I (P=7.58x10(-17)/4.84x10(-16)) or anticentromere autoantibodies (P=1.12x10(-3)/3.2x10(-5)), respectively. CONCLUSION The results of our genome-wide association study in Korean subjects indicate that the region of HLA-DPB1 and DPB2 contains the loci most susceptible to SSc in a Korean population. The confirmatory studies in US Caucasians indicate that specific SNPs of HLA-DPB1 and/or DPB2 are strongly associated with US Caucasian patients with SSc who are positive for anti-DNA topoisomerase I or anticentromere autoantibodies.
Annals of the Rheumatic Diseases | 2013
Yun Jong Lee; Yukihiro Horie; Graham R. Wallace; Yong Seok Choi; Ji Ah Park; Ji Yong Choi; Ran Song; Young-Mo Kang; Seong Wook Kang; Han Joo Baek; Nobuyoshi Kitaichi; Akira Meguro; Nobuhisa Mizuki; Kenichi Namba; Susumu Ishida; Jin Hyun Kim; Edyta Niemczyk; Eun Young Lee; Yeong Wook Song; Shigeaki Ohno; Eun Bong Lee
Objectives To identify non-major histocompatibility complex susceptible genes that might contribute to Behçets disease (BD). Methods We performed a genome-wide association study using DNA samples from a Korean population consisting of 379 BD patients and 800 controls. A replication study was performed in a Japanese population (363 BD patients and 272 controls). To evaluate the functional implication of the target single nucleotide polymorphisms (SNP), gene expression levels in peripheral T cells, allele-specific modulation of promoter activity and biological effect of mRNA knockdown were investigated. Results We found a novel association of BD to the GIMAP locus, mapped to chromosome 7q36.1 (rs1608157, p=6.01×10−8 in a minor allele dominant model; rs11769828, allele based p=1.60×10−6). A fine mapping study identified an association with four additional SNP: rs1522596 (OR=1.45, p=7.70×10−6) in GIMAP4; rs10266069 (OR=1.32, p=2.67×10−4) and rs10256482 (OR=1.27, p=5.27×10−4) in GIMAP2; and rs2286900 (OR=1.61, p=3.53×10−5) in GIMAP1 areas. Replication study using DNA samples from the Japanese population validated the significant association between BD and the GIMAP locus. The GIMAP4 promoter construct plasmid with the minor allele of rs1608157 displayed significantly lower activity than one with the major allele. Moreover, CD4 T cells from BD patients showed a lower level of GIMAP4 mRNA, and GIMAP4 knockdown was protective against Fas-mediated apoptosis. Conclusions These results suggest that a GIMAP cluster is a novel susceptibility locus for BD, which is involved in T-cell survival, and T-cell aberration can contribute to the development of BD.
The Journal of Clinical Pharmacology | 2013
Hee Jung Ryu; Ran Song; Hye Won Kim; Jinhyun Kim; Eun Young Lee; Yun Jong Lee; Yeong Wook Song; Eun Bong Lee
Allopurinol, one of the most commonly used uric acid–lowering agents, can cause serious adverse events. To investigate the risk factors for allopurinol‐induced adverse events, the authors enrolled 94 patients who developed allopurinol‐induced adverse events and 378 controls who were randomly chosen from 1934 patients who used allopurinol but did not develop any adverse events in this retrospective case control study. Univariate analysis showed that patients who developed allopurinol‐induced adverse events had more chronic kidney disease (46% vs 30%, P = .005), more hypertension (42% vs 30%, P = .036), less tumor lysis syndrome (P = .030), higher cholesterol (P = .013), and lower aspartate aminotransferase (P = .002) and alanine aminotransferase levels (P = .033) and more commonly used angiotensin receptor blockers (27% vs 15%, P = .007), colchicines (16% vs 5%, P = .010), or statins (19% vs 8%, P = .002) than those who did not. In multiple logistic regression analysis, the use of colchicines (odds ratio, 3.11; 95% confidence interval, 1.28‐7.58; P = .012) and statins (2.10; 1.03‐4.25; P = .041) was an independent risk factor predicting adverse events in allopurinol users. In conclusion, patients who use colchicine or statins are at significant risk for developing allopurinol‐induced adverse events.
Value in Health | 2012
Tae-Jin Lee; Bo Hyun Park; Hye Kyung Son; Ran Song; Ki Chul Shin; Eun Bong Lee; Yeong-Wook Song
OBJECTIVE To estimate the cost of illness (COI) and health-related quality of life (HRQOL) of rheumatoid arthritis (RA) according to four different levels of functional severity. METHODS A face-to-face interview survey was administered to patients with RA recruited at the Rheumatology Clinic of Seoul National University Hospital. Direct costs (medical costs [treatment, drug, private physiotherapy, traditional Chinese medicine, other alternative medicine], nonmedical costs [travel, dietary supplements, auxiliary device, home assistance]), indirect costs (productivity loss due to job loss and sick leave), and deterioration in the HRQOL of patients with RA were measured. Factors associated with the COI and the HRQOL were analyzed by using multiple regression and multivariate logistic regression. RESULTS A total of 196 patients were enrolled for this study. As RA functional severity worsened, the total costs increased accordingly (class I: 4,230,204 Korean won, class II: 7,250,674 Korean won, class III: 8,046,434 Korean won, class IV: 8,206,215 Korean won). Direct costs also increased with the severity of the functional status, with a sharp decrease in class IV. The average HRQOL score was 0.49, showing an evident impact of RA severity (class I: 0.67, class II: 0.50, class III: 0.29, class IV: 0.23). Functional class and comorbidity were significant determinants of the COI and the HRQOL. CONCLUSION Functional severity was a major factor associated with higher COI and lower HRQOL scores. Therefore, preventing the aggravation of functional severity is crucial for decreasing the COI and improving the HRQOL of patients with RA.
Rheumatology International | 2012
Ki Won Moon; Ran Song; Jinhyun Kim; Eun Young Lee; Eun Bong Lee; Yeong Wook Song
Rheumatology International | 2012
Ki Won Moon; Shin-Seok Lee; Jinhyun Kim; Ran Song; Eun Young Lee; Yeong Wook Song; Nicholas Bellamy; Eung Bong Lee
The Korean journal of internal medicine | 2011
Joon Wan Kim; Ran Song; Churl Hyun Im; Jinhyun Kim; Eun Young Lee; Eun Bong Lee; Yeong Wook Song
The Journal of The Korean Rheumatism Association | 2010
Hye Won Kim; Yeong Wook Song; Sung Hae Chang; Han Hee Ryu; Ran Song; Eun Bong Lee; Dae Won Son; You Young Kim
The Korean journal of internal medicine | 2009
Chan-Young Yun; Ran Song; Ki-Won Moon; Yun-Jong Lee; Yeong-Wook Song
The Journal of The Korean Rheumatism Association | 2009
Ki Won Moon; Yeong Wook Song; Ran Song; Chan Young Yun; Jae Ki Koh; Jinhyun Kim; Eun Young Lee; Eun Bong Lee